• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间歇性肾脏替代治疗强度对危重症患者的影响。

Impact of the intensity of intermittent renal replacement therapy in critically ill patients.

作者信息

Molina-Andújar Alicia, Alcubilla Pau, Santiago Pedro, Blasco Miquel, Cucchiari David, Piñeiro Gaston, Andrea Rut, Fernández Sara, Reverter Enric, Mercadal Jordi, Quintana Eduard, Poch Esteban

机构信息

Nephrology and Kidney Transplantation Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.

Clinical Pharmacology Department, Hospital Clínic, Barcelona, Spain.

出版信息

J Nephrol. 2021 Feb;34(1):105-112. doi: 10.1007/s40620-020-00760-x. Epub 2020 Jun 3.

DOI:10.1007/s40620-020-00760-x
PMID:32495232
Abstract

BACKGROUND

Intermittent renal replacement therapy (IRRT) is prescribed across intensive care units (ICU) worldwide. While research regarding the prescribed dialysis dose has not yielded results concerning mortality, it is still unknown whether the same applies to the actual delivered dose.

METHODS

We retrospectively analyzed two different cohorts of patients (562 IRRT sessions) who were admitted to the intensive care units at Hospital Clínic of Barcelona and required renal replacement therapy with IRRT. The first cohort included patients with acute kidney injury (AKI) (n = 42) and the second included patients already on chronic hemodialysis (CKD 5D) (n = 47). Only patients who had at least 3 recorded hemodialysis sessions in the ICU and with no previous continuous renal replacement therapy (CRRT) were included. The achieved dose was measured as Kt (L) by ionic dialysance and the primary endpoint was 90-day mortality.

RESULTS

Ninety-day mortality was 40.5% (n = 17) in the AKI cohort and 23.9% (n = 11) in the CKD 5D cohort with mean Kt of 43 ± 8.27 L and 47 ± 9.65 L respectively. Kt dose of IRRT was associated with 90-day mortality in the AKI cohort in a multivariate surveillance analysis adjusted for confounding factors (HR 0.935 [0.88-0.99], p = 0.02). Only the Kt dose and age remained statistically associated with the outcome in the AKI cohort.

CONCLUSIONS

Delivered dialysis dose as measured by ionic-dialysance Kt may be associated with survival in critically-ill patients with AKI, while it does not seem to affect outcomes in critically-ill CKD 5D patients. This exploratory analysis will need confirmation in larger prospective studies.

摘要

背景

间歇性肾脏替代治疗(IRRT)在全球范围内的重症监护病房(ICU)中均有应用。虽然关于规定透析剂量的研究尚未得出与死亡率相关的结果,但实际给予的剂量是否同样如此仍不清楚。

方法

我们回顾性分析了巴塞罗那临床医院重症监护病房收治的两个不同队列的患者(562次IRRT治疗),这些患者需要接受IRRT进行肾脏替代治疗。第一个队列包括急性肾损伤(AKI)患者(n = 42),第二个队列包括已接受慢性血液透析(CKD 5D)的患者(n = 47)。仅纳入在ICU至少有3次记录的血液透析治疗且此前未接受过连续性肾脏替代治疗(CRRT)的患者。通过离子透析测定达到的剂量为Kt(L),主要终点为90天死亡率。

结果

AKI队列的90天死亡率为40.5%(n = 17),CKD 5D队列的为23.9%(n = 11),平均Kt分别为43±8.27 L和47±9.65 L。在针对混杂因素进行调整的多变量监测分析中,IRRT的Kt剂量与AKI队列的90天死亡率相关(风险比0.935 [0.88 - 0.99],p = 0.0

相似文献

1
Impact of the intensity of intermittent renal replacement therapy in critically ill patients.间歇性肾脏替代治疗强度对危重症患者的影响。
J Nephrol. 2021 Feb;34(1):105-112. doi: 10.1007/s40620-020-00760-x. Epub 2020 Jun 3.
2
Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury.急性肾损伤重症患者的肾脏替代治疗给予剂量与死亡率
Crit Care. 2009;13(2):R57. doi: 10.1186/cc7784. Epub 2009 Apr 15.
3
Factors determining a low dose of haemodialysis as measured by ionic dialysance in critical patients with acute kidney injury.影响危重症急性肾损伤患者血液透析低剂量的因素:离子透析率测定。
Nefrologia. 2012 May 14;32(3):359-66. doi: 10.3265/Nefrologia.pre2012.Jan.11284. Epub 2012 Apr 17.
4
Economics of dialysis dependence following renal replacement therapy for critically ill acute kidney injury patients.危重症急性肾损伤患者肾脏替代治疗后透析依赖的经济学分析
Nephrol Dial Transplant. 2015 Jan;30(1):54-61. doi: 10.1093/ndt/gfu314. Epub 2014 Oct 17.
5
Long-Term Mortality and Health-Related Quality of Life After Continuous Versus Intermittent Renal Replacement Therapy in ICU Survivors: A Secondary Analysis of the Quality of Life After ICU Study.ICU 幸存者连续与间断肾脏替代治疗后的长期死亡率和健康相关生活质量:ICU 后生活质量研究的二次分析。
J Intensive Care Med. 2024 Jul;39(7):636-645. doi: 10.1177/08850666231224392. Epub 2024 Jan 9.
6
One- and three-year outcomes in patients treated with intermittent hemodialysis for acute kidney injury: prospective observational multicenter post-hoc FINNAKI study.间歇性血液透析治疗急性肾损伤患者的 1 年和 3 年结局:前瞻性观察性多中心事后 FINNAKI 研究。
Acta Anaesthesiol Scand. 2018 Nov;62(10):1452-1459. doi: 10.1111/aas.13203. Epub 2018 Jul 6.
7
[Effect of early initiation of continuous renal replacement therapy based on the KDIGO classification on the prognosis of critically ill patients with acute kidney injury].基于KDIGO分类的早期启动连续性肾脏替代治疗对急性肾损伤危重症患者预后的影响
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016 Mar;28(3):246-51.
8
Ionic dialysance: a new valid parameter for quantification of dialysis efficiency in acute renal failure?离子透析率:急性肾衰竭透析效率量化的一个新的有效参数?
Intensive Care Med. 2007 Mar;33(3):460-5. doi: 10.1007/s00134-006-0514-x. Epub 2007 Jan 18.
9
Renal replacement therapy in the ICU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy?重症监护病房中的肾脏替代治疗:间歇性血液透析、持续低效透析或连续性肾脏替代治疗?
Curr Opin Crit Care. 2018 Dec;24(6):437-442. doi: 10.1097/MCC.0000000000000541.
10
Acute kidney injury in critically ill COVID-19 infected patients requiring dialysis: experience from India and Pakistan.重症 COVID-19 感染患者需要透析的急性肾损伤:来自印度和巴基斯坦的经验。
BMC Nephrol. 2022 Sep 8;23(1):308. doi: 10.1186/s12882-022-02931-3.

本文引用的文献

1
[The monitoring of dialysis dose by ionic dialysance-based Kt reveals less dialysis adequacy than the Kt/V(UREA)-based measurement in critically ill patients with acute renal failure].[基于离子透析率的Kt监测显示,在急性肾衰竭的重症患者中,透析充分性低于基于尿素Kt/V的测量结果]
Nefrologia. 2010;30(2):232-5. doi: 10.3265/Nefrologia.pre2010.Mar.10336.